In a research report issued today, Oppenheimer analyst Christopher Marai assigned an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target. Marai …
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on PTC Therapeutics (NADSAQ:PTCT) with a $43 price …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a $43 price …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $34 price target. The analyst noted, “The FDA’s …
In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage on shares of PTC Therapeutics (PTCT). He issued a Buy …
